If you have Waldenstrom’s Macroglobulinemia (Lymphoplasmacytic Lymphoma), we need your help.
Lymphoma Canada, in partnership with the Canadian Organization for Rare Disorders (CORD) is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
Ibrutinib (Imbruvica) for patients with Waldenstrom’s Macroglobulinemia (WM) who have received at least one prior therapy
You can help by completing one of our surveys, which will provide us with the patient and caregiver input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
BY COMPLETING A SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE TREATMENTS IN CANADA.
You do not need to live in Canada to complete a survey.
The survey will be open until midnight Pacific Time on Wednesday, April 27th and should only take 10 minutes of your time.
You may access the survey by clicking the appropriate link below.
Survey for WM Patients with Ibrutinib (Imbruvica) Experience
Survey for WM Patients who have NOT been treated with Ibrutinib (Imbruvica)
Survey for Caregivers
Please share and help us spread the word.
Thank you for your support.
